Biotech Psoriasis Drugs Hit a Cost Ceiling

January 25, 2007

Are biotechnology companies reaching the limits of how much they can charge for their drugs? One sign of that is the sluggish sales of drugs for psoriasis. (New York Times)

Posted by

Posted in Biotech, News